We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Inadequate corrective and preventive action (CAPA) procedures prevented Amsino USA from detecting nonconforming manufacturing processes that led to the production of several air-filled syringes, according to an FDA warning letter.